Epilepsy Drugs Market in Europe - Market Analysis 2015-2019

ヨーロッパのてんかん(Epilepsy)治療薬市場

◆タイトル:Epilepsy Drugs Market in Europe - Market Analysis 2015-2019
◆商品コード:IRTNTR7242
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2015年9月30日
◆ページ数:64
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:欧州
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、ヨーロッパのてんかん(Epilepsy)治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、ヨーロッパのてんかん(Epilepsy)治療薬市場規模及び予測、市場シェア、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About epilepsy
Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth. When the underlying cause of the disease is unidentified, as is witnessed in the majority of cases, it is known as idiopathic epilepsy. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures.

Technavio’s analysts forecast the epilepsy drugs market in Europe to grow at a CAGR of 3.22% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the epilepsy drugs market in Europe for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of epilepsy.

Technavio’s report, Epilepsy Drugs Market in Europe 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

[Key vendors]
• Eisai
• GlaxoSmithKline
• Pfizer
• UCB

[Other prominent vendors]
• AbbVie
• Janssen Pharmaceuticals
• Lundbeck
• Meda
• Novartis
• Roche
• Shire
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Upsher-Smith
• Valeant Pharmaceuticals

[Market driver]
• Unmet medical needs
• For a full, detailed list, view our report

[Market challenge]
• Patent expiry
• For a full, detailed list, view our report

[Market trend]
• Reformulation of marketed drugs
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Epilepsy: An overview
About the disease
Types of epilepsy
Signs and symptoms
Diagnosis
Epidemiology
Economic burden

PART 06: Pipeline portfolio
Key information of few pipeline candidates

PART 07: Market landscape
Market overview
Epilepsy drugs market in Germany
Epilepsy drugs market in the UK
Five forces analysis

PART 08: Market segmentation by generation of drugs
Segmentation of epilepsy drugs market in Europe by generation of drugs

PART 09: Market drivers
Unmet medical needs
Rise in patient population
Promising drug pipeline

PART 10: Impact of drivers

PART 11: Market challenges
Expiry of patents
Stringent regulatory guidelines
Social stigma associated with epilepsy

PART 12: Impact of drivers and challenges

PART 13: Market trends
Reformulation of marketed drugs
Emergence of new-generation anti-epileptic drugs

PART 14: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors

PART 15: Key vendor analysis
Eisai
GlaxoSmithKline
Pfizer
UCB

PART 16: Appendix
List of abbreviations

PART 17: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Cost per person in Europe 2010
Exhibit 03: Pipeline portfolio
Exhibit 04: Epilepsy drugs market in Europe 2014-2019 ($ millions)
Exhibit 05: Epilepsy drugs market in Europe 2014
Exhibit 06: Epilepsy drugs market in Germany 2014-2019 ($ millions)
Exhibit 07: Epilepsy drugs market in the UK 2014-2019 ($ millions)
Exhibit 08: Five forces analysis
Exhibit 09: Segmentation of epilepsy drugs market in Europe by generation of drugs
Exhibit 10: Impact of drivers
Exhibit 11: Impact of drivers and challenges
Exhibit 12: Eisai: Key takeaways
Exhibit 13: Eisai: Fycompa product profile
Exhibit 14: Eisai: Revenue of Fycompa in EMEA 2013 and 2014 ($ millions)
Exhibit 15: Eisai: Inovelon product profile
Exhibit 16: Eisai: Revenue of Inovelon in EMEA 2013 and 2014 ($ millions)
Exhibit 17: Eisai: Zebinix product profile
Exhibit 18: Eisai: Revenue of Zebinix in EMEA 2013 and 2014 ($ millions)
Exhibit 19: Eisai: Zonegran product profile
Exhibit 20: Eisai: Revenue of Zonegran 2013 and 2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Key takeaways
Exhibit 22: GlaxoSmithKline: Lamictal product profile
Exhibit 23: GlaxoSmithKline: Revenue of Lamictal in Europe 2011-2014 ($ millions)
Exhibit 24: GlaxoSmithKline: Trobalt product profile
Exhibit 25: Pfizer: Key takeaways
Exhibit 26: Pfizer: Lyrica product profile
Exhibit 27: Pfizer: Revenue of Lyrica 2011-2014 ($ millions)
Exhibit 28: Pfizer: Neurontin product profile
Exhibit 29: Pfizer: Revenue of Neurontin 2011-2013 ($ millions)
Exhibit 30: UCB: Key takeaways
Exhibit 31: UCB: Keppra product profile
Exhibit 32: UCB: Revenue of Keppra in Europe 2011-2014 ($ millions)
Exhibit 33: UCB: Vimpat product profile
Exhibit 34: UCB: Revenue of Vimpat in Europe 2011-2014 ($ millions)
Exhibit 35: UCB: Product segmentation by revenue 2014
Exhibit 36: UCB: Product segmentation by revenue 2013 and 2014
Exhibit 37: UCB: Geographical segmentation by revenue 2014
Exhibit 38: UCB: Geographical segmentation by revenue 2013 and 2014



【掲載企業】

Eisai, UCB Pharma, Pfizer, GlaxoSmithKline, AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, Valeant Pharmaceuticals.

【資料のキーワード】

てんかん(Epilepsy)、てんかん治療薬、製薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[ヨーロッパのてんかん(Epilepsy)治療薬市場] (Epilepsy Drugs Market in Europe - Market Analysis 2015-2019 / IRTNTR7242)販売に関する免責事項
[ヨーロッパのてんかん(Epilepsy)治療薬市場] (Epilepsy Drugs Market in Europe - Market Analysis 2015-2019 / IRTNTR7242)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆